Bayer AG Action: Krebsmedikament says Erfolgspotenzial

Posted on September 10, 2024 by Vaseline

Bayer AG has conducted a phase I/II study for the lung medicine drug BAY 2927088. In 43 deferred patients, a study of a study was conducted …